


PRODUCT INFORMATION



Survodutide Item No. 40972

CAS Registry No.: 2805997-46-8
Formal Name: L-histidyl-1-aminocyclobutanecarbonyl-L-glutaminyglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L- α -aspartyl-L- α -glutamyl-L-arginyl-L-alanyl-L-alanyl-L-lysyl-L- α -aspartyl-L-phenylalanyl-L-isoleucyl-N⁶-[N-(17-carboxy-1-oxoheptadecyl)-L- γ -glutamylglycyl-L-serylglycyl-L-serylglycylglycyl]-L-lysyl-L-tryptophyl-L-leucyl-L- α -glutamyl-L-seryl-L-alaninamide



Synonym: BI-456906

Peptide Sequence: H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH₂ where Ac4c = 1-Aminocyclobutane-1-carboxylic Acid and X = A glycine-serine linker carrying a C18 di-acid

MF: C₁₉₂H₂₈₉N₄₇O₆₁

FW: 4,231.7

Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Survodutide is supplied as a solid. Aqueous solutions of survodutide can be prepared by directly dissolving the solid in aqueous buffers. Survodutide is soluble (\geq 10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Survodutide is a dual peptide agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR).¹ It increases cAMP accumulation in CHO-K1 cells expressing GLP-1R or GCGR in reporter assays (EC₅₀s = 0.33 and 0.52 nM, respectively) and potentiates glucose-induced insulin secretion in isolated mouse, rat, and perfused human pancreatic islets. Survodutide (3 and 30 nmol/kg per day) reduces body weight and food intake in diet-induced obese mice, but the reduction in food intake diminishes over time and returns to baseline within approximately 15 days. It reduces the levels of hepatic triglycerides and cholesterol, as well as plasma levels of glucagon, cholesterol, triglycerides, alanine transaminase (ALT), aspartate aminotransferase (AST), insulin, and leptin in the same mice. Survodutide (10 nmol/kg per day) also increases energy expenditure in diet-induced obese mice.

Reference

1. Zimmermann, T., Thomas, L., Baader-Pagler, T., *et al.* BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. *Mol. Metab.* **66**:101633, (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM